Alecensa (alectinib)

Information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor.

Anaplastic lymphoma kinase (ALK) belongs to a family of proteins called receptor tyrosine kinases (RTKs), which are involved in the growth of cells and the development of new blood vessels that supply them. In patients with ALK-positive non-small cell lung cancer (NSCLC), an abnormal form of ALK is produced that stimulates the cancer cells to divide and grow in an uncontrolled fashion.1

Treatment options for people with ALK+ mNSCLC include therapies called ALK inhibitors that target abnormal ALK proteins. ALK inhibitors work by blocking the abnormal ALK protein responsible for the growth and spread of ALK+ mNSCLC.2


In Bangladesh Alecensa is approved for the following indications.3

  • Alecensa is indicated for the first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
  • Alecensa is indicated for the treatment of patients with ALK-positive, locally advanced or metastatic NSCLC who have progressed on or are intolerant to crizotinib.

 

For more disease and medicine related queries you may discuss with your physician.

 

In Bangladesh Alecensa is available as

Capsules 150 mg

 

References

1. Alecensa | European Medicines Agency [Internet; cited 2020, March 17]. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa

2. What is ALECENSA® (alectinib) [Internet; cited 2020, March 17]. Retrieved from https://www.alecensa.com/patient/what-is-alk-positive-mnsclc/about-alecensa.html

3. Alecensa Product Information _ BD Ro 5424802 _ October 2017